Broker Newswire
  • Home
  • Latest News
  • Investing
    • Acquisitions
    • Broker Related
    • Online Trading
    • Cryptocurrencies
    • Stocks
  • Markets
    • Earnings
    • OTC Markets
    • Penny Stocks
  • Personal Finance
    • Saving money
    • Retirement
  • Economy
  • Tech
    • Enterprise
    • Internet
SUBSCRIBE
No Result
View All Result
  • Home
  • Latest News
  • Investing
    • Acquisitions
    • Broker Related
    • Online Trading
    • Cryptocurrencies
    • Stocks
  • Markets
    • Earnings
    • OTC Markets
    • Penny Stocks
  • Personal Finance
    • Saving money
    • Retirement
  • Economy
  • Tech
    • Enterprise
    • Internet
No Result
View All Result
Broker Newswire
No Result
View All Result
Home Latest News IPO News

Poxel Interested In Conducting Registered IPO in the United States

by Jay Helton
January 21, 2020
1 min read
0
Poxel Interested In Conducting Registered IPO in the United States
Share on FacebookShare on Twitter

RELATED STORIES

Volkswagen must pay damages

Volkswagen must pay damages to buyers of manipulated diesel cars

May 25, 2020
Future Cloud Banking and Fintech

Future Cloud Predictions for Banking and Fintech Sector

April 23, 2020

LYON, France–( BUSINESS WIRE )–POXEL S.A. (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it plans to conduct a registered initial public offering in the United States. The timing, number of securities and price of […]

Poxel, which is based out of Lyon, France, is an innovative biopharmaceutical company. The company specializes in the development of drugs to treat metabolic diseases. Most notably, Poxel focuses on the development of new type 2 diabetes medications. Their leading compound, Imeglimin, has completed Phase 2 clinical development in the United States and Europe. The compound achieved proof-of-concept in 2 Phase 2a trials and manages to achieve primary and secondary endpoints, during a Phase 2b dose-ranging trial.

The company, which originated in 2009, currently employs 18 people. The company’s stock began trading on the Euronext Paris exchange on February 6, 2016 under the POXEL ticker. The stock’s IPO price was set was EUR 6.66. It has a 1 year high of 16.75 and closed the day’s trading at 13.72. Those looking for more information about Poxel should visit their website.

Source: businesswire
Tags: initialofferingpharmaceuticalpixelpublic
Create your Web Presence with Namecheap

Recent Posts

  • Bitcoin and crypto spending is allowed by PayPal Now
  • The event in the live stream: Apple releases 5G-capable iPhone – Business
  • Volkswagen thriller: An unpopular supplier, audio recordings and a dead man
  • Tencent and WeChat also affected: Why Trump’s TikTok ban could harm Silicon Valley
  • Hacker attack on Twitter: “Group of young people” is supposed to be behind the attack on the social media platform

Category

  • Acquisitions
  • Broker Related
  • Earnings Reports
  • Economy
  • Enterprise
  • General
  • Internet
  • Investing
  • IPO News
  • Latest News
  • Layoffs
  • Markets
  • Online Trading
  • Opinion
  • OTC Markets
  • Penny Stocks
  • Personal Finance
  • Retirement
  • Saving money
  • Stocks
  • Technology

About Us

Broker Newswire (BN) is an exciting new online publication, which targets finances, brokers, mortgage and markets. BN, which is the nation’s leading provider of real estate, finance and market news and analysis.

  • About
  • Advertise
  • Privacy & Policy
  • Feedback

© 2021 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Home
  • Latest News
  • Investing
    • Acquisitions
    • Broker Related
    • Cryptocurrencies
    • Online Trading
    • Stocks
  • Markets
    • Earnings Reports
    • OTC Markets
    • Penny Stocks
  • Personal Finance
    • Retirement
    • Saving money
  • Economy
  • Tech
    • Enterprise
    • Internet
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.